Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by ... Read More
-
Cancer / Tumor Profiling
... 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Immunoassays Technology, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$6.7 Billion by the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia Therapeutics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of ... Read More
-
Non-Melanoma Skin Cancer
... at a CAGR of 4.4% over the analysis period 2024-2030. Basal Cell Carcinoma (BCC) Indication, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$835.6 Million by ... Read More
-
Oncology Information Systems
... at a CAGR of 6.2% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$5.5 Billion by the end of ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Basal Cell Carcinoma Treatment
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$7.6 Billion by the ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$12.1 Billion by the end of ... Read More
-
Endometrial Cancer Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Metastatic Bone Disease
... at a CAGR of 6.7% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$12.3 Billion by the end of the ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Cervical Cancer Treatment
... at a CAGR of 6.0% over the analysis period 2024-2030. Squamous Cell Carcinoma (SCC) Treatment, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.1 Billion by ... Read More
-
Breast Cancer Liquid Biopsy
... 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Liquid Biopsy Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.4% CAGR and reach US$819.3 Million ... Read More
-
Cancer Registry Software
... at a CAGR of 9.6% over the analysis period 2024-2030. Standalone Software, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$116.6 Million by the end of ... Read More
-
Particle Therapy
... CAGR of 8.8% over the analysis period 2024-2030. Proton Therapy, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Antineoplastic Agents
... CAGR of 7.3% over the analysis period 2024-2030. Chemotherapeutic Agents Application, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$137.9 Billion by the end of the ... Read More
-
Alpha Emitters
... CAGR of 20.9% over the analysis period 2024-2030. Bone Metastasis Application, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$993.8 Million by the end of the ... Read More
Research Assistance
